Information Provided By:
Fly News Breaks for January 8, 2020
Jan 8, 2020 | 05:27 EDT
Goldman Sachs analyst Graig Suvannavejh initiated coverage of Horizon Therapeutics with a Neutral rating and $35 price target. The analyst views the shares as "richly valued" and sees no obvious potential stock-moving 2020 catalysts.
News For HZNP From the Last 2 Days
There are no results for your query HZNP